At the news
? NEUTRALIMPACT 4/10 6-K filed Jul 29, 2026 at 17:08 ET
BioNTech (BNTX) announced via 6-K that the European Commission has granted marketing authorization for its 2026-2027 COVID-19 vaccine formula targeting the XFG variant. The approval, valid across the EU plus Iceland, Liechtenstein, and Norway, allows BioNTech and Pfizer to supply the updated monovalent vaccine ahead of the respiratory season. Manufacturing at risk has already commenced, but no financial terms or revenue impact were disclosed.
- European Commission authorized the 2026-2027 XFG-adapted COVID-19 vaccine for individuals 6 months and older.
- Authorization is valid in all 27 EU member states, Iceland, Liechtenstein, and Norway.
- Manufacturing at risk has been initiated by Pfizer and BioNTech to ensure supply readiness.
- More than 5 billion doses of the Pfizer-BioNTech COVID-19 vaccines have been distributed globally.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access